RxDoctor Payments Data

Monica White

Nurse Practitioner · Longview, TXNPI 1235145558

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Myriad Genetic Laboratories, Inc. accounts for 67.7% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2022 at $7,476 and has fallen 69.6% since, to $2,274 in 2025. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,400in general payments, 2019–2025

Across 186 payments — averaging $120.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myriad Genetic Laboratories, Inc.$15K
  • AbbVie$2K
  • Daiichi Sankyo Inc.$2K
  • Lilly USA, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$461
  • GSK$318
  • plus $2K from 28 others
$95,709in research payments, 2019–2025

Across 2 payments — averaging $47,854 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$96K

What the payments were for

  • Consulting fees$11,82553%
  • Speaking & faculty fees$3,45015%
  • Travel & lodging$1,8268%
  • Food & beverage$4,95122%
  • Education$3482%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,400 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$43,424
Medicare patients
218
Services billed
1,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Potassium Chloride20$151

Paid to pharmacies, not to this prescriber.

Other nurse practitioner in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →